Article Text

Download PDFPDF

OP0041 All-cause, cardiovascular and malignancy related mortality in systemic lupus erythematosus (SLE): a population-based study
  1. B Moghaddam1,
  2. JA Avina-Zubieta2,3,
  3. EC Sayre2
  1. 1Division of Medicine, University of British Columbia, Vancouver
  2. 2Arthritis Research Canada, Richmond
  3. 3Division of Rheumatology, University of British Columbia, Vancouver, Canada


Background SLE is associated with increased risk of overall mortality; however morality trends due to specific causes including cardiovascular disease (CVD), malignancies or other causes are largely unknown.

Objectives Our objective was to assess trends in cause-specific mortality among SLE patients between January 1, 1997 and December 31, 2012 in a general population-based context.

Methods We conducted a population-based matched cohort on SLE patients diagnosed between January 1,1997 and December 31,2012 using an administrative health database from the province of British Columbia, Canada. We identified all incident cases of SLE and up to 10 non-SLE controls matched on sex, age, and calendar year of study entry. The cohort was divided into two cohorts based on year of SLE diagnosis (1997–2004 and 2005–2012). All-cause mortality and cause-specific incidence of death rates (IR) were calculated. Cox proportional hazard regression models were used to estimate the mortality hazard ratios (HR), adjusting for possible confounders (i.e. Charlson Comorbidity Index, number of outpatient visits, hospitalization, cardiovascular medications, glucocorticoids and NSAIDs at baseline).

Results 4238 SLE and 42380 matched controls were studied. SLE patients had significantly increased all-cause mortality with HR 1.29 (95% CI, 1.15–1.46) and increased cause-specific mortality from CVD and other causes with HRs of 1.43 (95% CI, 1.15 -1.79) and 1.74 (95% CI, 1.46–2.09), respectively. The cohorts did not differ in the rate of death from malignancy. SLE patients had an approximately 2-fold increase in death from other causes in both early (HR 1.86 (95% CI 1.33–2.60)) and recent cohorts (HR 1.90 (95% CI 1.42–2.56)). There was no significant improvement in all-cause and cause-specific mortality trends between the two cohorts.

Table 1.

Overall and cause-specific mortality in SLE patients compared to general population; HR, hazard ratio

Conclusions This study demonstrates that despite advances in therapy with novel biologic agents, there are no significant differences in all-cause and CVD mortality from SLE between early and recent cohorts. Death from other causes, which includes a composite of death related to for example renal disease and infections, remains high suggesting areas for future targeted research and therapy.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.